P424 Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
| Autor: | Andrea Borenich, Heimo H. Wenzl, Andreas Blesl, Wolfgang Petritsch, Christoph Högenauer, F Baumann-Durchschein, S Mestel, Lukas Binder, Gudrun Pregartner, Patrizia Kump, Andrea Berghold |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Crohn's disease business.industry medicine.medical_treatment Gastroenterology General Medicine Bowel resection medicine.disease Ulcerative colitis Inflammatory bowel disease Infliximab Anti-Tumor Necrosis Factor Therapy Internal medicine medicine Adalimumab business medicine.drug Colectomy |
| Zdroj: | Journal of Crohn's and Colitis. 15:S427-S428 |
| ISSN: | 1876-4479 1873-9946 |
| Popis: | Background Anti-TNF therapy is still the most frequently used first-line biologic treatment in inflammatory bowel disease (IBD). This study aimed to determine length of treatment persistence and to describe reasons for discontinuation of first-line anti-TNF therapy used in the standard care of IBD patients. Methods A single-center, real-world, retrospective study including IBD patients (Crohn’s disease (CD), ulcerative colitis (UC), IBD unclassified (IBD-U)), who received an anti-TNF therapy in the last 20 years at the study center, was conducted. Length of first-line anti-TNF therapy, differences in treatment duration between infliximab (IFX) and adalimumab (ADA) and between CD and UC, reasons for discontinuation, side effects leading to cessation, treatment following first-line anti-TNF therapy, rates of surgery and death, and factors being associated with treatment failure were assessed. Results 586 patients were identified as having received first-line anti-TNF therapy at the study center. 48 patients were excluded due to shortness of available data. 538 patients (CD: 367, UC: 147, IBD-U: 24) with a median follow-up of 8.1 years were included in the analysis. Median (IQR) treatment persistence was 21.0 (6.0, 57.0) months in the total cohort. Treatment withdrawal arose frequently (40%) within the first year of therapy and treatment persistence was longer in CD compared to UC (CD: 27.0 (8.0, 71.0) months, UC: 11.0 (3.0, 34) months, p Conclusion Treatment persistence of first-line anti-TNF therapy is limited in IBD patients due to a large proportion of treatment failures and side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|